A Phase I Dose Finding Study of RAD001 in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer.

Trial Profile

A Phase I Dose Finding Study of RAD001 in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Jul 2015

At a glance

  • Drugs Everolimus (Primary) ; Capecitabine; Oxaliplatin
  • Indications Gastric cancer
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 03 Jul 2013 Planned end date changed from 1 Nov 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 09 Apr 2012 Planned number of patients changed from 20 to 40 as reported by ClinicalTrials.gov.
    • 09 Apr 2012 Planned end date changed from 1 Feb 2012 to 1 Nov 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top